University of Hertfordshire

From the same journal

By the same authors

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment

Research output: Contribution to journalArticlepeer-review

Standard

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment. / Specka, Michael; Kuhlmann, Thomas; Bonnet, Udo; Sawazki, Jürgen; Schaaf, Luzia; Kühnhold, Stefan; Steinert, Renate; Grigoleit, Torsten; Eich, Helmut; Zeiske, Benita; Niedersteberg, Antje; Steiner, Katharina; Schifano, Fabrizio; Scherbaum, Norbert.

In: Frontiers in Psychiatry, Vol. 13, 868346, 01.06.2022.

Research output: Contribution to journalArticlepeer-review

Harvard

Specka, M, Kuhlmann, T, Bonnet, U, Sawazki, J, Schaaf, L, Kühnhold, S, Steinert, R, Grigoleit, T, Eich, H, Zeiske, B, Niedersteberg, A, Steiner, K, Schifano, F & Scherbaum, N 2022, 'Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment', Frontiers in Psychiatry, vol. 13, 868346. https://doi.org/10.3389/fpsyt.2022.868346

APA

Specka, M., Kuhlmann, T., Bonnet, U., Sawazki, J., Schaaf, L., Kühnhold, S., Steinert, R., Grigoleit, T., Eich, H., Zeiske, B., Niedersteberg, A., Steiner, K., Schifano, F., & Scherbaum, N. (2022). Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment. Frontiers in Psychiatry, 13, [868346]. https://doi.org/10.3389/fpsyt.2022.868346

Vancouver

Author

Specka, Michael ; Kuhlmann, Thomas ; Bonnet, Udo ; Sawazki, Jürgen ; Schaaf, Luzia ; Kühnhold, Stefan ; Steinert, Renate ; Grigoleit, Torsten ; Eich, Helmut ; Zeiske, Benita ; Niedersteberg, Antje ; Steiner, Katharina ; Schifano, Fabrizio ; Scherbaum, Norbert. / Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment. In: Frontiers in Psychiatry. 2022 ; Vol. 13.

Bibtex

@article{fa1c32bb25744106b3fcdab4cac7cbfa,
title = "Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment",
abstract = "Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use in European heroin dependents. Method: A cross-sectional multicenter study, carried out with the means of both standardized interviews and urine toxicology enhanced screening, in a sample of opioid addicted patients referred for an in-patient detoxification treatment. Results: Sample size included here n = 256 patients; prior to admission, 63.7% were prescribed with an opioid maintenance treatment. Lifetime use of heroin and opioid analgesics was reported by 99.2 and 30.4%, respectively. Lifetime NSO/fentanyl use was reported by 8.7% (n = 22); a regular use was reported by 1.6% (n = 4), and ingestion over the 30 days prior to admission by 0.8% (n = 2). Most typically, patients had started with a regular consumption of heroin, followed by maintenance opioids; opioid analgesics; and by NSO. Self-reported data were corroborated by the toxicology screenings carried out; no evidence was here identified for the presence of heroin being contaminated by fentanyl/derivatives. Discussion: NSO and also opioid analgesics did not play a relevant role in the development and the course of opioid/opioid use disorders in German patients referred for an inpatient detoxification treatment.",
keywords = "Psychiatry, new synthetic opioids, fentanyl, fentanyl analogs, inpatient detoxification, opioids, opioid dependence",
author = "Michael Specka and Thomas Kuhlmann and Udo Bonnet and J{\"u}rgen Sawazki and Luzia Schaaf and Stefan K{\"u}hnhold and Renate Steinert and Torsten Grigoleit and Helmut Eich and Benita Zeiske and Antje Niedersteberg and Katharina Steiner and Fabrizio Schifano and Norbert Scherbaum",
note = "{\textcopyright} 2022 Specka, Kuhlmann, Bonnet, Sawazki, Schaaf, K{\"u}hnhold, Steinert, Grigoleit, Eich, Zeiske, Niedersteberg, Steiner, Schifano and Scherbaum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/",
year = "2022",
month = jun,
day = "1",
doi = "10.3389/fpsyt.2022.868346",
language = "English",
volume = "13",
journal = "Frontiers in Psychiatry",
issn = "1664-0640",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment

AU - Specka, Michael

AU - Kuhlmann, Thomas

AU - Bonnet, Udo

AU - Sawazki, Jürgen

AU - Schaaf, Luzia

AU - Kühnhold, Stefan

AU - Steinert, Renate

AU - Grigoleit, Torsten

AU - Eich, Helmut

AU - Zeiske, Benita

AU - Niedersteberg, Antje

AU - Steiner, Katharina

AU - Schifano, Fabrizio

AU - Scherbaum, Norbert

N1 - © 2022 Specka, Kuhlmann, Bonnet, Sawazki, Schaaf, Kühnhold, Steinert, Grigoleit, Eich, Zeiske, Niedersteberg, Steiner, Schifano and Scherbaum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use in European heroin dependents. Method: A cross-sectional multicenter study, carried out with the means of both standardized interviews and urine toxicology enhanced screening, in a sample of opioid addicted patients referred for an in-patient detoxification treatment. Results: Sample size included here n = 256 patients; prior to admission, 63.7% were prescribed with an opioid maintenance treatment. Lifetime use of heroin and opioid analgesics was reported by 99.2 and 30.4%, respectively. Lifetime NSO/fentanyl use was reported by 8.7% (n = 22); a regular use was reported by 1.6% (n = 4), and ingestion over the 30 days prior to admission by 0.8% (n = 2). Most typically, patients had started with a regular consumption of heroin, followed by maintenance opioids; opioid analgesics; and by NSO. Self-reported data were corroborated by the toxicology screenings carried out; no evidence was here identified for the presence of heroin being contaminated by fentanyl/derivatives. Discussion: NSO and also opioid analgesics did not play a relevant role in the development and the course of opioid/opioid use disorders in German patients referred for an inpatient detoxification treatment.

AB - Introduction: Over the last decade, the use of New/Novel Synthetic Opioids (NSO) has emerged as an increasing problem, and especially so in the USA. However, only little is known about the prevalence and history of NSO use in European heroin dependents. Method: A cross-sectional multicenter study, carried out with the means of both standardized interviews and urine toxicology enhanced screening, in a sample of opioid addicted patients referred for an in-patient detoxification treatment. Results: Sample size included here n = 256 patients; prior to admission, 63.7% were prescribed with an opioid maintenance treatment. Lifetime use of heroin and opioid analgesics was reported by 99.2 and 30.4%, respectively. Lifetime NSO/fentanyl use was reported by 8.7% (n = 22); a regular use was reported by 1.6% (n = 4), and ingestion over the 30 days prior to admission by 0.8% (n = 2). Most typically, patients had started with a regular consumption of heroin, followed by maintenance opioids; opioid analgesics; and by NSO. Self-reported data were corroborated by the toxicology screenings carried out; no evidence was here identified for the presence of heroin being contaminated by fentanyl/derivatives. Discussion: NSO and also opioid analgesics did not play a relevant role in the development and the course of opioid/opioid use disorders in German patients referred for an inpatient detoxification treatment.

KW - Psychiatry

KW - new synthetic opioids

KW - fentanyl

KW - fentanyl analogs

KW - inpatient detoxification

KW - opioids

KW - opioid dependence

U2 - 10.3389/fpsyt.2022.868346

DO - 10.3389/fpsyt.2022.868346

M3 - Article

VL - 13

JO - Frontiers in Psychiatry

JF - Frontiers in Psychiatry

SN - 1664-0640

M1 - 868346

ER -